Moomoo AIのまとめ
Virpax Pharmaceuticals, a preclinical-stage pharmaceutical company, reported a net loss of $21.7 million for the year ended December 31, 2022, compared to a net loss of $12.1 million for the previous year. The company's accumulated deficit reached approximately $44.4 million. Despite the losses, Virpax has cash reserves of around $19.0 million. The company is involved in litigation with potential damages up to $35.0 million, but has accrued $2 million for this purpose. Virpax's primary source of capital has been through equity securities issuance, including a successful initial public offering (IPO) and an underwritten public offering in 2021. The company's financial statements have been prepared under the assumption that it will continue as a going concern, although there is substantial doubt due to ongoing losses and litigation uncertainties. Virpax is focused on developing non-opioid pain management treatments and CNS disorder treatments. The company relies on third-party contract manufacturing organizations (CMOs) for production and has entered into various research and licensing agreements to advance its product candidates.
Virpax Pharmaceuticals, a preclinical-stage pharmaceutical company, reported a net loss of $21.7 million for the year ended December 31, 2022, compared to a net loss of $12.1 million for the previous year. The company's accumulated deficit reached approximately $44.4 million. Despite the losses, Virpax has cash reserves of around $19.0 million. The company is involved in litigation with potential damages up to $35.0 million, but has accrued $2 million for this purpose. Virpax's primary source of capital has been through equity securities issuance, including a successful initial public offering (IPO) and an underwritten public offering in 2021. The company's financial statements have been prepared under the assumption that it will continue as a going concern, although there is substantial doubt due to ongoing losses and litigation uncertainties. Virpax is focused on developing non-opioid pain management treatments and CNS disorder treatments. The company relies on third-party contract manufacturing organizations (CMOs) for production and has entered into various research and licensing agreements to advance its product candidates.
Virpax製薬は、臨床前段階の医薬品会社で、2022年12月31日の決算期に2170万ドルの純損失を報告し、前年の1210万ドルの純損失と比較しています。同社の累積赤字は約4440万ドルに達しました。損失にもかかわらず、Virpaxは約1900万ドルの現金準備があります。同社は3500万ドルまでの損害を伴う訴訟に巻き込まれていますが、この目的のために200万ドルを計上しています。Virpaxの主要な資本源は、IPO（新規株式公開）と2021年の公開株式募集を含む株式証券の発行を通じて確保されています。同社の財務諸表は、継続する限り会社が存続するものとして作成されていますが、持続的な損失と訴訟...すべて展開
Virpax製薬は、臨床前段階の医薬品会社で、2022年12月31日の決算期に2170万ドルの純損失を報告し、前年の1210万ドルの純損失と比較しています。同社の累積赤字は約4440万ドルに達しました。損失にもかかわらず、Virpaxは約1900万ドルの現金準備があります。同社は3500万ドルまでの損害を伴う訴訟に巻き込まれていますが、この目的のために200万ドルを計上しています。Virpaxの主要な資本源は、IPO（新規株式公開）と2021年の公開株式募集を含む株式証券の発行を通じて確保されています。同社の財務諸表は、継続する限り会社が存続するものとして作成されていますが、持続的な損失と訴訟の不確実性があるため、かなりの疑念があります。Virpaxは、非オピオイド性疼痛管理治療および中枢神経系障害治療の開発に焦点を当てています。同社は製造のために第三者の契約製造組織（CMO）を利用し、製品候補の進展のためにさまざまな研究およびライセンス契約を締結しています。
役に立った
役に立たない
